Results highlight robust Sonata System design and its potential to become a standard of care for fibroid treatment REDWOOD CITY, Calif.–(BUSINESS WIRE)–Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the results from their pivotal IDE trial for the [...]
Endeavour Vision invested in Medartis. Located in Basel, Switzerland, the company develops, manufactures and distributes medical internal fixation devices and surgical instruments offered in system solutions for small bone fractures focusing on the extremities. Medartis was founded in 1997 by Dr. Thomas Straumann. The company launched its first products [...]
Novel uterus-preserving Sonata System is first incision-free treatment to address majority of fibroids transcervically REDWOOD CITY, Calif.–(BUSINESS WIRE)–Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for uterine fibroids, today announced its submission to the FDA of its 510(k) Premarket Notification for the Sonata® System, [...]
ST. PAUL, Minn., Oct. 23, 2017 /PRNewswire/ — EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the Company has formally changed its name to ReShape Lifesciences Inc. (NASDAQ: RSLS). The new name, effective today, reflects the Company’s expansion [...]
EnteroMedics Announces Acquisition Of ReShape Medical Acquisition Adds Approved, Revenue-Generating Balloon Technology for Obesity ST. PAUL, Minn., Oct. 3, 2017 /PRNewswire/ — EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has acquired ReShape [...]
VentureMed Group Raises $15 Million Series B Equity Financing TOLEDO, Ohio, Aug. 15, 2017 /PRNewswire/ — VentureMed Group®, Inc., (“VMG” or the “Company”) a medical device company developing and commercializing next-generation endovascular products to treat patients suffering from peripheral artery disease (PAD), today announced it had raised $15 [...]
Zurich-Schlieren, May 30, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the first patient was dosed in the phase 2 multiple myeloma study of its lead oncology asset MP0250. In the first phase 2 [...]
Zurich-Schlieren, May 12, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, Ph.D., cofounder of the company, as Chief Executive Officer and to nominate him [...]
Long-term venture capital investors holding reduced to 28% of share capital. Private investors acquired shares from venture capitalist investors in secondary block trades. Zurich-Schlieren, April 6, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today reported changes [...]
Symetis launches its IPO on Euronext Paris Symetis develops, produces and markets heart valve replacement solutions for the treatment of severe cardiac valve conditions. The company plans to raise € 55.8 million that could be increased to approximately € 64.1 million in the event of full exercise of [...]